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 The bacterium Vibrio alginolyticus, an opportunistic pathogen in humans, has a type III 27 
secretion system (T3SS) that is responsible for its cytotoxicity toward eukaryotic cells. The 28 
effector of T3SS that is responsible for the cytotoxicity had not been identified. Here we 29 
demonstrate that VepA, a homolog of the T3SS effector in V. parahaemolyticus, is required 30 
for cytotoxicity in V. alginolyticus. VepA induces lysosomal membrane permeabilization, and 31 
it allows the leakage of only small molecules into the cytosol. Our findings revealed that 32 
VepA induces cathepsin-independent cell death in mammalian cells. The ferrous ion, one of 33 
the small molecules in the lysosome contents, appears to be involved in the cell death caused 34 
by V. alginolyticus VepA. 35 
 36 
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Vibrio alginolyticus is a halophilic, Gram-negative rod-shaped bacterium naturally 41 
distributed in marine and estuarine waters. This bacterium is known as an opportunistic 42 
pathogen for both humans and marine animals [1–3]. In humans, it causes medical problems 43 
such as wound infection [4–7], ear infection [8–12], and eye infection [13–15]. The incidence 44 
of V. alginolyticus infection was reported to be increasing, and this infection may develop into 45 
an emerging disease due to climate change issues [16]. A complete understanding of the 46 
virulence mechanism of V. alginolyticus is necessary to prevent future outbreaks. 47 
The pathogenicity of V. alginolyticus has been described both in vivo (lethality in a 48 
mouse model) [17] and in vitro (cytotoxic activity toward several mammalian cell lines) [18]. 49 
The killing potency shown in those studies indicated that V. alginolyticus possesses virulence 50 
factor(s) that allow infection through the ability to overcome antibacterial immune responses 51 
such as phagocytosis, and the ability to obtain nutrition from the dead cells. As such a 52 
virulence factor in V. alginolyticus, Zhao et al. [17] reported that the deletion of type III 53 
secretion system (T3SS) apparatus gene reduces the cytotoxicity toward mammalian cell 54 
lines. A T3SS is a syringe-like apparatus that introduces specific proteins known as effectors 55 
into the cytoplasm of eukaryotic host cells. Injected effectors allow bacteria to manipulate the 56 
host cells' functions and cause diseases [19–21]. A variety of effectors are known to show 57 
specific cytotoxicity mechanisms in various bacterial species, but the effector of T3SS that is 58 
responsible for the cytotoxicity in V. alginolyticus has been unclear. 59 
The V. alginolyticus T3SS gene cluster is evolutionally close to T3SS1 in 60 
V. parahaemolyticus, which is dominantly responsible for cytotoxicity [22]. Another T3SS in 61 
V. parahaemolyticus, T3SS2, which is involved in enterotoxicity, is absent in V. alginolyticus. 62 
Among the effectors of T3SS1 in V. parahaemolyticus, VepA (which has also been referred to 63 
as VopQ and as VP1680) plays a significant role in its cytotoxicity [23, 24]. Since 64 
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V. alginolyticus has a gene encoding a VepA homolog in the T3SS gene cluster, we 65 
hypothesized that the VepA homolog also has an important contribution to the cytotoxicity. 66 
In this study, we constructed a vepA-deletion mutant in V. alginolyticus to analyze its 67 
role in the cytotoxicity of V. alginolyticus. We observed that V. alginolyticus infection led to 68 
size-specific lysosome membrane permeabilization (LMP) in a VepA-dependent manner. We 69 
also use our results in a discussion of why the small-molecule leakage from lysosomes is 70 
related to cell death in V. alginolyticus infection. 71 
 72 
Materials and Methods 73 
Bacterial strains, plasmids, and culture conditions 74 
The bacterial strains and plasmids used in this study are listed in Table 1. We used 75 
V. alginolyticus ATCC 17749 [25] as the parent strain for the construction of gene-deletion 76 
mutant. We used the Escherichia coli DH5α [26] for general plasmid manipulation; E. coli 77 
DH5α(λpir) was used to amplify the R6K-origin-containing plasmids, and E. coli RHO3 [27] 78 
was used as a conjugation donor for V. alginolyticus. V. alginolyticus strains were routinely 79 
cultured in Luria-Bertani (LB) 3% NaCl medium (1% tryptone, 0.5% yeast extract, 3% NaCl) 80 
at 37°C, and the E. coli strains were grown in LB medium (Lennox) (1% tryptone, 0.5% yeast 81 
extract, 0.5% NaCl) at 37°C. E. coli RHO3 was grown in LB medium supplemented with 100 82 
µg/ml 2,6-diaminopimelic acid. Chloramphenicol (30 µg/ml), ampicillin (50 µg/ml), or 83 
kanamycin (100 µg/ml) was added to grow bacteria harboring the plasmid containing the 84 
corresponding resistance gene. 85 
HeLa cells were cultured in Dulbecco's modified Eagle's medium (DMEM, Sigma, St. 86 
Louis, MO) supplemented with 10% (v/v) inactivated fetal bovine serum (FBS) (Biowest, 87 
Nuaillé, France) at 37°C under 5% CO2. DMEM or minimum essential medium/Earle's 88 
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balanced salts (MEM/EBSS, Gibco, Grand Island, NY) without phenol red supplemented with 89 
10% (v/v) inactivated FBS was used during incubation in the infection experiment. 90 
 91 
Construction of a mobilizable vector for gene replacement 92 
We constructed a mobilizable vector for gene replacement carrying the recognition site of 93 
meganuclease I-SceI, pKU66, by inserting the oriT region into pSG76-C [28] at the NotI site. 94 
We amplified the oriT region from pUC18T-mini-Tn7T-Gm [29] using primers P064 (5'-95 
GCGGCCGCTATCAGAGCTTATCGGCCAG-3'; the underlining indicates a NotI site) and 96 
P065 (5'-GCGGCCGCGGGGATTCCTTAAGGTATAC-3'; the underlining indicates a NotI 97 
site). 98 
 99 
Construction of mobilizable vectors for gene expression 100 
We constructed pEX18Km by replacing the ampicillin resistance gene on pEX18Ap [30] with 101 
the kanamycin resistance gene at the AatII and AhdI sites. We amplified the kanamycin 102 
marker from pHSG298 (Takara Bio, Shiga, Japan) using primers P394 (5'- 103 
GACGTCGATCTGATCCTTCAACTCAG-3'; the underlining indicates an AatII site) and 104 
P395 (5'-GACTCCCCGTCTGCTCTGCCAGTGTTACAAC-3'; the underlining indicates an 105 
AhdI site). 106 
We constructed pHSG398T by inserting oriT into the AflIII site of pHSG398 (Takara 107 
Bio). The oriT region was amplified by using primers P127 (5'-108 
ACATGTATCAGAGCTTATCGGCCAG-3'; the underlining indicates an AflIII site) and 109 
P128 (5'-ACATGTGGGGATTCCTTAAGGTATAC-3'; the underlining indicates an AflIII 110 
site). 111 
 112 
Construction of an I-SceI expression vector 113 
  
6 
We amplified the promoter region of the elongation factor thermo unstable (EF-Tu) in 114 
V. alginolyticus I.029 by using primers P406 (5'- GAATTCAGCGGGTTACCCTGTACTAG-115 
3'; the underlining indicates an EcoRI site) and P407 (5'-116 
GATCGTGTTCCTTCCTAGTTATG-3'). 117 
The I-SceI gene was amplified from pST76-ASceP [28] with the use of the primers 118 
P408 (5'-CATAACTAGGAAGGAACACGATCATGCATCAAAAAAACCAGGTA-3'; the 119 
underlining indicates a sequence overlapping to the 3' region of the EF-Tu promoter) and 120 
P409 (5'-CAAAGGGAAAACTGTCCATAC-3'). The two DNA fragments were spliced by 121 
overlap extension polymerase chain reaction (PCR). The recombinant fragment was ligated 122 
into pGEM-T Easy (Promega, Madison, WI) to obtain pOU246. We cloned an EcoRI-SphI 123 
fragment of pOU246 carrying the I-SceI gene with the EF-Tu promoter into the same sites of 124 
pEX18Km, resulting in pOU257. 125 
 126 
Construction of a vepA-deletion mutant and a vscC-deletion mutant 127 
We constructed ∆vepA as described [28] with several modifications. A DNA fragment with 128 
the vepA-deletion was constructed by overlap extension PCR as described [31] used the 129 
following primers: P787 (5'-GGATCCAACGTGGAGTAAGGATGTGAAAA-3'; underlining 130 
indicates a BamHI site), P788 (5'-131 
TGAAATTACACCCAGCCTTCTGCGCTGATTTTTTGTGTTGTATTAACCAT-3'; 132 
underlining indicates complementary region to P789), P789 (5'-133 
GCAGAAGGCTGGGTGTAATTTCA-3') and P790 (5'-134 
GAGCTCGAAGTCACTGAAGAGAGATTTTCGA-3'; underlining indicates a SacI site). 135 
We cloned this fragment into pKU66 at the BamHI and SacI sites, resulting in pOU549. 136 
E. coli RHO3 harboring plasmid pOU549 was conjugated with V. alginolyticus ATCC 17749, 137 
and the resultant transconjugant was conjugated to E. coli RHO3 harboring pOU257. The 138 
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transconjugants were selected on LB 2% NaCl agar plates containing antibiotic for the 139 
responsible plasmid. The vepA-deletion was confirmed by colony PCR using primers P787 140 
and P790, and by sequencing of the PCR products. The remaining pOU257 was eliminated by 141 
inoculation into LB 3% NaCl medium containing 5% sucrose. 142 
The construction of ∆vscC was performed using the same method as that used for the 143 
∆vepA construction. The primers used to amplify the vscC-deletion fragment were P793 (5'-144 
GAATTCCGGTTGCGAAAGTATGGCAATG-3'; the underlining indicates an EcoRI site), 145 
P794 (5'-AGGAACAACACTCACTGCGCATA-3'), P795 (5'-146 
TATGCGCAGTGAGTGTTGTTCCTCGCCCTTCAGAGGAGTCTTAACC-3'; the 147 
underlining indicates complementary region to P794) and P796 (5'-148 
GGATCCGCAGATCGAGTTTCTGTGTTCGG-3'; the underlining indicates a BamHI site). 149 
This fragment was cloned into pKU66 at EcoRI and BamHI sites, resulting in pOU553. The 150 
vscC deletion was confirmed by colony PCR using primers P793 and P796 and by sequencing 151 
of the PCR products. 152 
 153 
Construction of a vepA expression vector 154 
We amplified the DNA fragment containing vepA from the gDNA by using primers P791 (5'-155 
GCTGAATTCAATGGTTAATACAACACAAAAAATCAGCCAAAGC-3'; underlining 156 
indicates an EcoRI site) and P792 (5'-GCTGGATCCTTACACCCAGCCTTCTGCCAAG-3'; 157 
underlining indicates a BamHI site). The PCR product was cloned into EcoRI and BamHI 158 
sites of pHSG398T, which yielded pOU550. 159 
 160 
Cytotoxicity assay 161 
HeLa cells were seeded into a 96-well plate at 3×104 cells/well, and then incubated at 37°C 162 
under 5% CO2 for 48 hr. The cells were washed with DMEM or MEM/EBBS medium 163 
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without phenol red, and then infected with V. alginolyticus at a multiplicity of infection 164 
(MOI) of 100 for 4 hr. A ten-times dilution of V. alginolyticus at the optical density at 600 nm 165 
(OD600) of 1.0 is equal to 3–4×108 CFU/ml on an LB 1% NaCl agar plate. We added 10 µl of 166 
these dilution cultures to 3–4×104 of HeLa cell culture to obtain the MOI of 100. 167 
We measured the release of lactate dehydrogenase (LDH) into the medium by using a 168 
Cytotoxicity Detection KitPLUS (LDH) (Roche, Mannheim, Germany) according to the 169 
manufacturer's instructions. The percentage of LDH release was calculated based on the 170 
following equation: [OD490 of experimental release – OD490 of spontaneous release]/(OD490 of 171 
maximum release – OD490 of spontaneous release) × 100. The spontaneous release is the 172 
amount of LDH released from the cytoplasm of uninfected cells, and the maximum release is 173 
the total amount of LDH released upon the complete lysis of uninfected cells. 174 
 175 
AO relocation assay 176 
The acridine orange (AO) relocation assay was performed as described [24]. We used 177 
fluorescence microscopy (Biozero BZ-8000, Keyence, Tokyo) to analyze the AO-stained 178 
cells. 179 
 180 
Fluorescent-dextran translocation 181 
Fluorescent-dextran translocation was observed as described [32]. Before infection, HeLa 182 
cells were incubated in 100 µg/ml fluorescein isothiocyanate (FITC)-dextran for 16 hr. We 183 
analyzed fluorescent dextran in the HeLa cells by fluorescence microscopy. 184 
 185 
Inhibition of cathepsin and reactive oxygen species (ROS), LMP induction, and iron 186 
chelation 187 
HeLa cells were pretreated with 100 µM E-64d, a broad-spectrum cathepsin inhibitor, for 16 188 
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hr before infection. The cells were challenged with 3 mM L-Leucyl-L-Leucine methyl ester 189 
(LLOMe) for 4 hr to induce LMP. To chelate iron, we used 100 µM 2,2'-bipyridyl (BIP). To 190 
inhibit reactive oxygen species (ROS), we used 5 mM N-acetyl cysteine (NAC) or 250 µM 191 
Trolox. 192 
 193 
Statistical analysis 194 
The two-tailed Student's t-test was used for the statistical analyses. 195 
 196 
Results 197 
VepA contributes to HeLa cell cytotoxicity in V. alginolyticus infection 198 
We chose V. alginolyticus strain ATCC17749, which was shown to be highly virulent in an in 199 
vivo infection model [18]. VepA (N646_0746) in this strain is homologous to that in 200 
V. parahaemolyticus, with 88% sequence similarity (435 aa/493 aa). 201 
To examine the contribution of VepA to the cytotoxicity toward human cells, we 202 
performed the LDH release cytotoxicity assay after 4 hr of bacterial infection against HeLa 203 
cells (Fig. 1). The T3SS apparatus gene mutant, ∆vscC, showed significantly less cytotoxicity 204 
than the wild-type (WT). ∆vepA also showed significantly less cytotoxicity. The vepA 205 
complimentary strain, ∆vepA/vepA completely restored the cytotoxicity (similar to the WT), 206 
whereas ∆vepA/vector did not. To test the results of the LDH release cytotoxicity assay, we 207 
also performed propidium iodine (PI) staining. The results were similar to those of the LDH 208 
release cytotoxicity assay (data not shown). These results indicate that mainly VepA is 209 
responsible for the cytotoxicity of V. alginolyticus. 210 
 211 
VepA in V. alginolyticus induced lysosomal membrane permeabilization (LMP) 212 
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It was reported that V. parahaemolyticus VepA induces LMP in mammalian cells [24, 33]. 213 
Here we therefore examined the integrity of lysosomes in V. alginolyticus-infected cells by 214 
using acridine orange (AO) (Fig. 2). AO is a metachromatic dye that emits red fluorescence at 215 
low pH (e.g., in lysosomes) and emits green fluorescence at neutral pH (e.g., in the cytosol) 216 
[34]. 217 
In uninfected HeLa cells, we observed small red fluorescent dots, which reflect an 218 
accumulation of the dye in lysosomes. In the WT infection, the appearance of red dots was 219 
disappeared and the intensity of the green fluorescence in the cytosol was increased. In 220 
contrast, in the ∆vepA infection, the appearance of red dots was comparable to that in the 221 
uninfected cells, and the green fluorescence enhancement was not observed. In the 222 
∆vepA/vepA infection, the fluorescence pattern reverted to one similar to that obtained with 223 
the WT. These results indicate that V. alginolyticus infection induces the leakage of the 224 
lysosomal contents into the cytosol in a VepA-dependent manner. 225 
We observed that infection with either V. alginolyticus strain induced a morphological 226 
change of HeLa cells, i.e., cell rounding (Fig. 2). Since the ∆vepA infection also induced cell 227 
rounding, we can safely assume that this change is not due to VepA. On the other hand, the 228 
∆vscC strain did not affect the cell morphology (data not shown). Therefore, this change 229 
might be caused by other T3SS effectors, e.g., N646_0751, the homologue of VopS in 230 
V. parahaemolyticus [35]. 231 
 232 
The VepA-induced LMP in V. alginolyticus was not due to a lysosomal membrane rupture 233 
The molecular mass of AO is approx. 0.3 kDa. To determine whether VepA induces the 234 
release of only small molecules or lysosomal rupture, we observed the LMP in 235 
V. alginolyticus infection using larger molecules: FITC-dextran, with the molecular mass of 4 236 
or 10 kDa. It is well known that such macromolecules can be loaded into lysosomes to yield 237 
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green fluorescence punctates while the lysosomes are intact. When the lysosomes are 238 
ruptured, the FITC-dextran is released into the cytosol to yield diffuse green fluorescence. 239 
HeLa cells were treated with FITC-dextran for 16 hr to allow lysosomal uptake before 240 
infection or challenge with an LMP inducer, LLOMe. When FITC-dextran with the molecular 241 
mass of 10 kDa was preloaded (Fig. 3A), LLOMe-treated cells showed diffuse fluorescence 242 
enhancement in the cytosol. In contrast, the cells infected with the WT or ∆vepA did not 243 
exhibit the fluorescence diffusion into the cytosol, but the cells did show fluorescent 244 
punctates. Our experiments using FITC-dextran with the molecular mass of 4 kDa gave the 245 
same pattern (Fig. 3B). These results indicate that the VepA-mediated LMP allows the 246 
translocation of molecules smaller than 4 kDa. 247 
 248 
VepA-dependent cytotoxicity is not due to lysosomal cathepsin 249 
LMP-associated cell death is usually related to lysosomal cathepsin release [36]. Since the 250 
VepA-induced LMP in V. alginolyticus infection allowed the release of only molecules <4 251 
kDa, we hypothesized that lysosomal proteases with the molecular sizes >4 kDa (including 252 
cathepsins, the molecular masses of which is approx. 30 kDa) could not pass through the 253 
lysosomal membrane. To determine whether the VepA-mediated cell death is due to cathepsin 254 
release from lysosomes, we examined the effect of a broad-spectrum cathepsin inhibitor, E-255 
64d, on cell death. HeLa cells were treated with E-64d for 16 hr before challenge with 256 
LLOMe or a V. alginolyticus strain. The lysosomal rupture induced by LLOMe subsequently 257 
resulted in cell death, as reported [36], and cytotoxicity was reduced by E-64d treatment as 258 
expected (Fig. 4A). When the cells were challenged with the WT strain, the cell death rates 259 
were similar regardless of the E-64d treatment (Fig. 4A). These results suggest that cathepsin 260 
is not the major causative factor of V. alginolyticus cytotoxicity. 261 
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Since the lysosome is one of the iron-rich intracellular organelles, VepA might allow 262 
excessive iron release into the cytosol to induce cell death via ROS [37]. To investigate the 263 
roles of iron and ROS in cell death in V. alginolyticus infection, we compared their cytotoxic 264 
effects in the presence of an iron chelator, BIP, and an ROS scavenger, NAC or Trolox. In the 265 
presence of BIP, the cytotoxicity was significantly reduced. However, after the ROS 266 
scavenger treatment, the cytotoxicity was slightly reduced or not changed, respectively (Fig. 267 
4B). When we directly examined hydroxyl radicals by using hydroxyphenyl fluorescein, we 268 
observed no fluorescence in V. alginolyticus-infected cells (data not shown). 269 
 270 
Discussion 271 
The opportunistic pathogen V. alginolyticus has an active T3SS that is involved in its 272 
cytotoxicity [3, 17]. In V. parahaemolyticus, a T3SS effector, VepA, makes the major 273 
contribution to the cytotoxicity. Our present findings demonstrate that the VepA in 274 
V. alginolyticus plays a significant role in its cytotoxicity (Fig. 1). Since the vepA gene is 275 
conserved in several Vibrio species [38], it is possible that VepA-induced cell death is a 276 
common pathogenic mechanism among the species. 277 
Our present results obtained using an in vitro infection model also showed that 278 
V. alginolyticus induces the leakage of the 0.3-kDa lysosomotropic dye AO into the cytosol in 279 
a VepA-dependent manner (Fig. 2). Molecules larger than 4 kDa were retained in the 280 
lysosomes (Fig. 3). We thus speculate that V. alginolyticus VepA induces size-specific LMP. 281 
These results are consistent with those obtained by Sreelatha et al. [33], i.e., 282 
V. parahaemolyticus VepA induces LMP, which only allows the release of molecules <4 kDa. 283 
Sreelatha et al. also proposed that VepA forms pores with an estimated diameter of 18 Å in 284 
liposomes. Further studies are necessary to determine whether V. alginolyticus VepA forms 285 
such pores in the lysosomal membrane. 286 
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LMP results in cell death, which is usually related to lysosomal cathepsin release [36]. 287 
Since V. alginolyticus VepA induced size-specific LMP, i.e., <4 kDa, we can safely assume 288 
that this is not the case, since lysosomal proteases (e.g., cathepsins) have much larger 289 
molecular masses at approx. 30 kDa. To test this, we used the broad-spectrum cathepsin 290 
inhibitor E-64d to determine whether it inhibits the cell death. Since V. alginolyticus VepA 291 
induced cell death regardless of the presence of this inhibitor (Fig. 4A), the cell death is 292 
caused by a factor(s) other than cathepsins. We thus suspect that the involvement of 293 
lysosomal small molecules potentially harmful to the cells is responsible for the VepA-294 
induced cell death. 295 
The lysosome is a pool of redox-active iron capable of generating free radicals via the 296 
Fenton reaction [37]. We used the iron chelator BIP to examine whether iron mediates the 297 
VepA-induced cell death. Since iron chelation significantly reduced the cell death to a level 298 
that was almost the same as that observed with vepA-deleted V. alginolyticus infection, it 299 
appears that iron is an important mediator of VepA-dependent cell death (Fig. 4B). Our 300 
results support the observation by Matsuda et al. [24] that an iron chelator partially reduced 301 
the cytotoxicity in V. parahaemolyticus infection. 302 
Since it is well known that iron triggers cell death via ROS accumulation [37, 39], we 303 
examined the effects of ROS scavengers. NAC inhibited the cell death only slightly, but 304 
Trolox did not inhibit the cell death at all. Moreover, the growth rate of V. alginolyticus was 305 
not affected by the presence of BIP, NAC or Trolox. We therefore propose that iron induces 306 
cell death without ROS accumulation in this infection model. A study on yeast demonstrated 307 
that iron overload stimulates the sphingolipid production that leads to cell death, without ROS 308 
accumulation [37]. Additional studies are required to elucidate the function of iron in VepA-309 
induced cell death. 310 
In conclusion, our experiments demonstrated that VepA induced cathepsin-independent 311 
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cell death. We also observed that VepA induced size-specific LMP that allows only small 312 
molecules to be released into the cytosol. We propose that iron leakage from lysosomes plays 313 
an important role in this cell death mechanism. Further research is required to elucidate the 314 
underlying molecular mechanism, which might provide insights into the development of 315 
novel therapeutics that target the VepA-related cell death mechanism. 316 
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Table 1. Bacterial strains and plasmids 429 
Strain/Plasmid Relevant Genotype or Properties Reference or Source 
E. coli strains 
  
DH5α F- Φ80lacZΔM15 Δ(lacZYA-argF)U169 deoR 
recA1 endA1 hsdR17(rK− mK−) phoA supE44 
[26] 
DH5α(λpir) DH5α λpir H.P. Schweizer 
RHO3 SM10(λpir) Δasd:FRT ΔaphA:FRT [27] 
    
V. alginolyticus 
strains  
    
ATCC 17749 Wild-type strain   [25] 
∆vepA ATCC 17749 ∆vepA This study 
∆vscC ATCC 17749 ∆vscC This study 
∆vepA/vepA ∆vepA harboring pOU550 This study 
∆vepA/vector ∆vepA harboring pHSG398T 
 
This study 
Plasmids    
pGEM-T Easy AMPr; TA cloning vector Promega 
pSG76-C CMr; Suicide plasmid vector; I-SceI [28] 
pKU66 CMr; pSG76-C with oriT This study 
pHSG398 CMr; pUC-type cloning vector Takara Bio. 
pHSG398T CMr; pHSG398 with oriT This study 
pEX18Ap AMPr; cloning vector; sacB; oriT [30] 
pEX18Km KMr; pEX18Ap with AMPr replacement to KMr This study 
pHSG298 KMr; source of kanamycin resistance gene Takara Bio. 
pUC18T-mini-Tn7T-
Gm 
AMPr, GMr; source of oriT [29] 
  
20 
pST76A-SceP AMPr; source of I-SceI [28] 
pOU246 AMPr; pGEM-T Easy with EF-Tu promoter and I-
SceI 
This study 
pOU257 KMr; pEX18Km with EF-Tu promoter and I-SceI This study 
pOU549 CMr; pKU66 with ∆vepA recombinant DNA 
fragment 
This study 
pOU550 CMr; pHSG398T with vepA This study 
pOU553 CMr; pKU66 with ∆vscC recombinant DNA 
fragment 
This study 
AMP, ampicillin; CM, chloramphenicol; GM, gentamycin; KM, kanamycin. 430 
  431 
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FIGURE LEGENDS 432 
 433 
Fig. 1. VepA contribution to cytotoxicity toward HeLa cells. HeLa cells were infected with 434 
the wild-type strain (WT), a vscC-deletion mutant (ΔvscC), a vepA-deletion mutant (ΔvepA), 435 
or a vepA-deletion mutant carrying a vepA-expression plasmid or the empty vector 436 
(ΔvepA/vepA or ΔvepA/vector, respectively). We evaluated cytotoxicity at 4 hr after infection 437 
by measuring the amount of LDH released into the culture supernatant. Data are mean±SD. 438 
***P<0.001. 439 
 440 
Fig. 2. AO relocation assays results. HeLa cells were incubated with AO and then infected 441 
with the WT strain, a vepA-deletion mutant (ΔvepA), or a vepA-deletion mutant carrying a 442 
vepA-expression plasmid (ΔvepA/vepA) for 4 hr. AO emits red fluorescence in the lysosomes 443 
and green fluorescence in the cytosol. 444 
 445 
Fig. 3. LMP visualized by fluorescent dextran release. HeLa cells were incubated with 10-446 
kDa (A) or 4-kDa (B) FITC-dextran for 16 hr and then challenged with LLOMe or infected 447 
with the WT strain, vepA-deletion mutant (ΔvepA), or vepA-deletion mutant carrying a vepA-448 
expression plasmid (ΔvepA/vepA) for 4 hr. 449 
 450 
Fig. 4. Cytotoxicity of V. alginolyticus infection in cathepsin inhibition, iron chelation, and 451 
ROS inhibition. A, HeLa cells were pretreated with E-64d (E) and then challenged with 3 mM 452 
LLOMe or infected with the WT strain for 4 hr. B, HeLa cells were pretreated with an iron 453 
chelator (BIP) or an ROS scavenger (NAC or Trolox) and then infected with WT strain for 4 454 
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